Abstract: Among the various aspects of the present disclosure is the provision of compositions of CD163 targeting and theranostic agents and methods for use in detecting, monitoring, and evaluating CD163 associated diseases, disorders, and conditions.

Abstract: A method for manufacturing a low-carbon nitrogen-containing austenitic stainless steel bar sequentially includes smelting, electroslag remelting, and forging. During electroslag remelting, the steel ingot obtained in the smelting process is used as an electrode bar of the electroslag furnace and is remelted with specific slag and crystallized. The specific slag comprises CaF2 (65-70%), Al2O3 (15-20%), CaO (5-10%) and MgO (2-5%) in percentage by weight. Specific forging methods, including upsetting-and-drawing and radial forging, are used. In upsetting-and-drawing, the pass deformation is less than 35%, the pass reduction is 50-80 mm, the pass heating temperature is 1130-1150° C., and the pass deformation method is ellipse-ellipse-circle. The method can obtain the low-carbon high-strength nitrogen-containing austenitic stainless steel with uniformly distributed chemical composition, high purity and high strength.

Abstract: The present invention discloses a method for manufacturing a low-carbon nitrogen-containing austenitic stainless steel bar, which sequentially includes the following steps: smelting, electroslag remelting and forging; in the electroslag remelting process, the steel ingot obtained in the smelting process is used as an electrode bar of an electroslag furnace, remelting with specific slag and crystallizing; in the forging process, forging the crystallized steel ingot into a material by a specific forging method; the specific slag comprises CaF2 (65-70%), Al2O3 (15-20%), CaO (5-10%) and MgO (2-5%) in percentage by weight; specific forging methods include upsetting-and-drawing and radial forging, wherein the upsetting-and-drawing includes: a pass deformation is less than 35%, a pass reduction is 50-80 mm, a pass heating temperature is 1130-1150° C., and a pass deformation method is ellipse-ellipse-circle.

Abstract: The disclosure relates to a 2-(2,2-diarylethyl)-cyclic amine derivative or salt, a synthesis method, an application and a composition thereof. Biological activity test shows that this kind of 2-(2,2-diarylethyl)-cyclic amine derivative has good M-receptor antagonistic activity; and can be used as an active component of drugs for the treatment of the diseases mediated or regulated by muscarinic receptors, such as asthma, chronic obstructive pulmonary disease (COPD), overactive bladder (OAB), bronchospasm with chronic obstructive pulmonary disease, visceral spasm, irritable bowel syndrome, Parkinson's disease, depression or anxiety, schizophrenia and related mental diseases.

Abstract: The disclosure relates to a 2-(2,2-diarylethyl)-cyclic amine derivative or salt, a synthesis method, an application and a composition thereof. Biological activity test shows that this kind of 2-(2,2-diarylethyl)-cyclic amine derivative has good M-receptor antagonistic activity; and can be used as an active component of drugs for the treatment of the diseases mediated or regulated by muscarinic receptors, such as asthma, chronic obstructive pulmonary disease (COPD), overactive bladder (OAB), bronchospasm with chronic obstructive pulmonary disease, visceral spasm, irritable bowel syndrome, Parkinson's disease, depression or anxiety, schizophrenia and related mental diseases.

Abstract: A method for measuring the content of sterol and/or derivatives thereof by utilizing nuclear magnetic resonance technology. A nuclear magnetic resonance internal standard method is used, and a specific quantitative peak of sterol and/or derivatives thereof is selected, to accurately measure the (total) content of the sterol and/or derivatives thereof. The method can accurately measure the content of sterol and/or derivatives thereof in extracts of animals, plants and/or microorganisms, food, medicines or cosmetics.

Abstract: The present document discloses a method and apparatus for traffic control. The method includes: receiving a service requirement from a PGW and an Internet-surfing policy corresponding to the service requirement; acquiring traffic control information from an upper-layer application according to the service requirement and the Internet-surfing policy, herein the traffic control information includes: state information of a policy counter to be monitored and a traffic slice corresponding to the state information of the policy counter; and issuing the state information of the policy counter and the traffic slice to the PGW. The technical solution provided by the present document achieves an effect of opening the traffic control to the upper-layer application, saves the unnecessary overhead and investment of a network layer, and improves the capability of a system to quickly deploy a traffic-refined application.

Abstract: A method of treating nervous system diseases associated with dopamine receptors comprising administering a patent in need a compound having a structure of general formula (I) or a pharmaceutical acceptable salt, hydrate, or solvate thereof in a pharmaceutically effective amount, and a method of making the compound having the structure of general formula (I) or a pharmaceutical acceptable salt, hydrate, or solvate thereof. The compound of formula (I) has multiple pharmacological functions such as the functions of activating opioid receptors and blocking dopamine D2 receptors, and has good physicochemical properties and oral bioavailability. General animal experiments show that such a compound has significant and long-lasting analgesic and calming effects and can be used to treat pain and other mental illnesses.

Abstract: A method of treating nervous system diseases associated with dopamine receptors comprising administering a patent in need a compound having a structure of general formula (I) or a pharmaceutical acceptable salt, hydrate, or solvate thereof in a pharmaceutically effective amount, and a method of making the compound having the structure of general formula (I) or a pharmaceutical acceptable salt, hydrate, or solvate thereof. The compound of formula (I) has multiple pharmacological functions such as the functions of activating opioid receptors and blocking dopamine D2 receptors, and has good physicochemical properties and oral bioavailability. General animal experiments show that such a compound has significant and long-lasting analgesic and calming effects and can be used to treat pain and other mental illnesses.